COMMUNIQUÉS West-GlobeNewswire

Voyager Reports First Quarter 2025 Financial and Operating Results
06/05/2025
– Tau silencing gene therapy VY1706 to be featured in oral presentation at ASGCT 2025; has shown up to 73% knockdown of tau mRNA in the CNS in NHPs following a single IV dose of 1.3e13 vg/kg – – Recent Voyager data on [...]
Standard BioTools Reports First Quarter 2025 Financial Results
06/05/2025
SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the first quarter ended March 31, 2025. [...]
Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
06/05/2025
– Phase 3 results from ENLIGHTEN 2 pivotal Phase 3 trial of LYR 210 in Chronic Rhinosinusitis (CRS) expected in Q2 2025 – WATERTOWN, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra [...]
CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3
06/05/2025
-Initial CTX310™ Phase 1 clinical data demonstrates dose-dependent decreases in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 81% in LDL, with a well-tolerated [...]
Late-Breaking Interim STENOVA Data Presented at Digestive Disease Week® 2025 Demonstrate Potential of AGMB-129 in Fibrostenosing Crohn’s Disease
06/05/2025
Antwerp, Belgium, May 6, 2025 – Agomab Therapeutics NV (“Agomab”) today announced late-breaking interim data from the ongoing STENOVA 1 Phase 2a clinical trial for AGMB-129, an oral gastro-intestinal (GI)-restricted [...]
Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering
06/05/2025
HOUSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the [...]
Annual NMDP(SM) Gala in New York City Raises Over a Half Million Dollars, Enabling More Patients to Receive Life-Saving Cell Therapy
06/05/2025
MINNEAPOLIS, May 06, 2025 (GLOBE NEWSWIRE) -- NMDP SM hosted its annual gala in New York on Thursday, May 1, raising $525,000-- funds which will support patient financial assistance and innovative cell therapy research [...]
Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq
06/05/2025
CHICAGO, May 06, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of [...]
Avadel Pharmaceuticals Announces Favorable Ruling in Appeal of Delaware Court Injunction
06/05/2025
- With this ruling, Avadel can seek and be granted FDA approval for LUMRYZ in Idiopathic Hypersomnia - - Federal Circuit decision permits new clinical trials and further development of LUMRYZ™ for the treatment of [...]
Informations relatives au nombre total de droits de vote et d’actions composant le capital
06/05/2025
Informations relatives au nombre total de droits de vote et d’actions composant le capital Nantes, le 6 mai 2025 – En application de l’article L. 233-8 II du Code de commerce et de l’article 223-16 du Règlement général [...]
EssilorLuxottica: Disclosure of transactions in own shares
06/05/2025
Disclosure of transactions in own shares Paris, France (May 6, 2025 - 6:00 pm) – In accordance with the authorization granted by the Annual Shareholders’ Meeting on April 30, 2024, EssilorLuxottica declares that on [...]
EssilorLuxottica: Déclaration de transactions sur actions propres
06/05/2025
Déclaration de transactions sur actions propres Paris, France (6 mai 2025, 18h00) – Conformément à l’autorisation octroyée par l’Assemblée Générale du 30 avril 2024, EssilorLuxottica déclare que le 29 avril 2025, les [...]
Beacon Therapeutics Announces Positive Phase 2 Interim 6-Month Data from DAWN Trial of Laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) at ARVO 2025
06/05/2025
Data showed improvements across several key measures of visual function, including low luminance visual acuity and microperimetry Laru-zova was generally well-tolerated by DAWN participants at 6 months LONDON and [...]
Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social
06/05/2025
Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 06 mai 2025 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui [...]
Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social
06/05/2025
Communiqué de Presse Information relative au nombre total de droits de vote e t d’actions composant le capital social Dijon, le 06 mai 2025 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui [...]
Pasithea Therapeutics Announces Pricing of $5 Million Public Offering
06/05/2025
MIAMI, May 06, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics, Corp. (“Pasithea,” or the “Company”) (Nasdaq: KTTA; KTTAW), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK [...]
RapidPulse Announces Patient Enrollment Initiated in Pivotal Ischemic Stroke Study
06/05/2025
MIAMI, May 06, 2025 (GLOBE NEWSWIRE) -- RapidPulse, Inc., a Delaware corporation headquartered in Miami, Florida focused on improving the treatment success rate for acute ischemic stroke (AIS), announced patient [...]
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
06/05/2025
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 6 May 2025 at 18.00 EEST Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]
Coloplast A/S - Announcement no. 04/2025 - Interim Financial Report, H1 2024/25
06/05/2025
Interim financial results, H1 2024/25 1 October 2024 - 31 March 2025 Coloplast delivered 6% organic growth in Q2, impacted by the product recall in Interventional Urology and a softer quarter in Ostomy Care. Q2 EBIT [...]

Pages